{
    "clinical_study": {
        "@rank": "31965", 
        "acronym": "AFLUCO4", 
        "arm_group": [
            {
                "arm_group_label": "Fludrocortisone 100 \u03bcg", 
                "arm_group_type": "Experimental", 
                "description": "100 \u03bcg/day (25 \u00b5g four times daily) of fludrocortisone during 5 days\nInvestigations the sixth day"
            }, 
            {
                "arm_group_label": "Fludrocortisone 200 \u03bcg", 
                "arm_group_type": "Experimental", 
                "description": "200 \u03bcg/day (50 \u00b5g four times daily) of fludrocortisone during 5 days\nInvestigations the sixth day"
            }, 
            {
                "arm_group_label": "Fludrocortisone 400 \u03bcg", 
                "arm_group_type": "Experimental", 
                "description": "400 \u03bcg/day (100 \u00b5g four times daily) of fludrocortisone during 5 days\nInvestigations the sixth day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (four times daily) during 5 days\nInvestigations the sixth day"
            }
        ], 
        "brief_summary": {
            "textblock": "Fludrocortisone, in association with hydrocortisone, has demonstrated an improvement in\n      survival in septic shock patients with relative adrenal insufficiency. However, the utility\n      of low doses of steroids and in particular of mineralocorticoids in septic shock is still\n      discussed.\n\n      The purpose of the investigators study is to investigate the effects of 3 increasing doses\n      of fludrocortisone (100 \u03bcg, 200 \u03bcg, 400 \u03bcg) in order to determine which dose allows the best\n      pressor response to phenylephrine in healthy volunteers, and simultaneously assess their\n      respective hemodynamic and biological effects."
        }, 
        "brief_title": "Fludrocortisone in Healthy Volunteers (AFLUCO4)", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "In a previous study (AFLUCO2) in healthy volunteers with saline-induced hypoaldosteronism,\n      the investigators found that single doses of both hydrocortisone and fludrocortisone induced\n      a significant decrease in the pressor response to phenylephrine, probably due to a rapid\n      non-genomic vasodilatory mechanism, and that these effects were additive.\n\n      The investigators also showed that, at the doses used in septic shock, hydrocortisone\n      induced more pronounced mineralocorticoid effects than fludrocortisone and also induced\n      systemic hemodynamic effects whereas fludrocortisone did not.\n\n      The investigators now want to perform a dose-response study under normal conditions (ie\n      without saline-induced hypoaldosteronism) and after repeated administrations, to determine\n      the optimal dose of fludrocortisone that allows an increase in the pressor response to\n      phenylephrine and to characterize its concomitant hemodynamic and biological effects.\n\n      This placebo-controlled, randomized, double-blind, cross-over, 4-periods (fludrocortisone\n      100 \u03bcg/day, 200 \u03bcg/day, 400 \u03bcg/day, or placebo) study aims to investigate hemodynamic and\n      biological effects of fludrocortisone administered orally during 5 days, in healthy\n      volunteers.\n\n      Each period will be separated from the next one by a washout interval of at least 14 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men aged 20 to 25 years\n\n          -  Body Mass Index between 20 kg/m\u00b2 and 25 kg/m\u00b2\n\n          -  Nonsmoker since at least 6 months\n\n          -  Normal clinical examination, electrocardiogram and transthoracic echocardiography\n\n          -  Normal routine biological parameters\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  History of significant allergy\n\n          -  Resting heart rate < 50 bpm\n\n          -  Subjects with abnormal hepatic or renal function, or cardiovascular, pulmonary,\n             endocrine or psychiatric disease\n\n          -  Ongoing medication during the study\n\n          -  Alcohol consumption more than 30g/day or drug addiction\n\n          -  Exclusion period mentioned on the national registry for clinical trials volunteers.\n\n          -  Subject under legal protection"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "25 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140918", 
            "org_study_id": "2013-004794-27"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fludrocortisone 100 \u03bcg", 
                "description": "Fludrocortisone 100 \u03bcg/day", 
                "intervention_name": "Fludrocortisone 100 \u03bcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fludrocortisone 200 \u03bcg", 
                "description": "Fludrocortisone 200 \u03bcg/day", 
                "intervention_name": "Fludrocortisone 200 \u03bcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fludrocortisone 400 \u03bcg", 
                "description": "Fludrocortisone 400 \u03bcg/day", 
                "intervention_name": "Fludrocortisone 400 \u03bcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fludrocortisone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fludrocortisone", 
            "Mineralocorticoids", 
            "Hemodynamics", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "contact": {
                "email": "bruno.laviolle@chu-rennes.fr", 
                "last_name": "Bruno Laviolle, MD", 
                "phone": "33 (0)2.99.28.96.68"
            }, 
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France", 
                    "zip": "35033"
                }, 
                "name": "Rennes University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Bruno Laviolle, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Fabrice Lain\u00e9, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Erwan Donal, MD PHD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "Hemodynamic and Biological Effects of 3 Increasing Doses of Fludrocortisone in Healthy Volunteers", 
        "overall_contact": {
            "email": "bruno.laviolle@chu-rennes.fr", 
            "last_name": "Bruno Laviolle, MD", 
            "phone": "33 (0)2.99.28.96.68"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre d'Investigation Clinique Inserm 0203, Service de Pharmacologie Clinique, H\u00f4pital de Pontchaillou", 
                "last_name": "Bruno Laviolle, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre d'Investigation Clinique Inserm 0203, Service de Pharmacologie Clinique, H\u00f4pital de Pontchaillou", 
                "last_name": "Eric Bellissant, MD/PHD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Phenylephrine mean blood pressor dose-response relationship.", 
            "safety_issue": "No", 
            "time_frame": "1.5 hour after fludrocortisone administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140918"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cardiac systolic and diastolic function assessed par transthoracic echocardiography during phenylephrine administration", 
                "safety_issue": "No", 
                "time_frame": "between 1.5 and 2.5 hours after  fludrocortisone administration"
            }, 
            {
                "description": "Systolic, diastolic and mean arterial pressures, heart rate, peripheral pulse pressure, cardiac output, stroke volume, systemic vascular resistances", 
                "measure": "Systemic hemodynamic parameters", 
                "safety_issue": "No", 
                "time_frame": "30min before and 1h, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration"
            }, 
            {
                "measure": "Arterial stiffness : carotid-femoral pulse wave velocity", 
                "safety_issue": "No", 
                "time_frame": "30min before and 1h, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration"
            }, 
            {
                "description": "Aortic systolic, diastolic and mean arterial pressures, central pulse pressure, central pressure augmentation index (AIx)", 
                "measure": "Central aortic hemodynamic parameters", 
                "safety_issue": "No", 
                "time_frame": "30min before and 1h, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration"
            }, 
            {
                "description": "Blood electrolytes, urea, creatinine, glucose, renin, aldosterone", 
                "measure": "Plasma parameters", 
                "safety_issue": "No", 
                "time_frame": "30min before and 1h, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration"
            }, 
            {
                "description": "Diuresis, urinary electrolytes, urea, creatinine, glucose", 
                "measure": "Urinary parameters", 
                "safety_issue": "No", 
                "time_frame": "30min before and 2h, 4h, 6h after fludrocortisone administration"
            }, 
            {
                "measure": "Area under the plasma concentration versus time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Just before and 5min, 10min, 20min, 30min, 1h, 1h30, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration"
            }, 
            {
                "measure": "Plasma half-life of fludrocortisone", 
                "safety_issue": "No", 
                "time_frame": "Just before and 5min, 10min, 20min, 30min, 1h, 1h30, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration"
            }, 
            {
                "measure": "Total Body Clearance", 
                "safety_issue": "No", 
                "time_frame": "Just before and 5min, 10min, 20min, 30min, 1h, 1h30, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration"
            }, 
            {
                "measure": "Apparent volume of distribution", 
                "safety_issue": "No", 
                "time_frame": "Just before and 5min, 10min, 20min, 30min, 1h, 1h30, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration"
            }
        ], 
        "source": "Rennes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rennes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}